Abstract | BACKGROUND: METHODS: RESULTS: Pre-treatment with CpG ODN significantly increased survival of neutropenic wt mice from 33% to 75% (P = 0.0003) but did not protect neutropenic TLR9-/- mice. The protective effect of CpG ODN was associated with an enhanced production of interleukin ( IL)-12/IL-23p40 with sustained increased levels in serum and spleen at least for 17 days after conditioning compared to buffer-treated animals. CpG-treated neutropenic wt mice showed reduced bacterial concentrations and increased recruitment of Ly6ChighCCR2+ monocytes in brain and spleen 42 h after infection. The levels of macrophage inflammatory protein 1α (MIP-1α) and interferon gamma (IFN-γ) in spleen were higher 42 h after infection in CpG-treated compared to buffer-treated neutropenic animals. In immunocompetent mice, prophylaxis with CpG ODN did not significantly increase survival compared to the buffer group (60% vs. 45%, P = 0.2). CONCLUSIONS: These findings suggest that systemic administration of CpG ODN may help to prevent bacterial CNS infections in immunocompromised individuals.
|
Authors | Sandra Ribes, Tanja Meister, Martina Ott, Sandra Redlich, Hana Janova, Uwe-Karsten Hanisch, Stefan Nessler, Roland Nau |
Journal | Journal of neuroinflammation
(J Neuroinflammation)
Vol. 11
Pg. 14
(Jan 23 2014)
ISSN: 1742-2094 [Electronic] England |
PMID | 24456653
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, CD
- Cytokines
- Oligodeoxyribonucleotides
- Tlr9 protein, mouse
- Toll-Like Receptor 9
- Guanidine
|
Topics |
- Animals
- Antigens, CD
(metabolism)
- Central Nervous System
(drug effects, microbiology, pathology)
- Cytokines
(metabolism)
- Disease Models, Animal
- Drug Administration Schedule
- Escherichia coli
(physiology)
- Escherichia coli Infections
(prevention & control)
- Flow Cytometry
- Guanidine
(chemistry)
- Meningoencephalitis
(prevention & control)
- Mice
- Mice, Knockout
- Oligodeoxyribonucleotides
(therapeutic use)
- Spleen
(microbiology, pathology)
- Toll-Like Receptor 9
(deficiency)
|